Effects and side effects of long-term administration of oral antitumor agents for patients with hepatocellular carcinoma. Especially, relation to aggravation of liver function.

DOI PubMed 1 Citations

Bibliographic Information

Other Title
  • 肝細胞癌に対する内服抗癌剤療法の効果と副作用　　特に肝機能悪化の問題について
  • Especially, Relation to Aggravation of Liver Function
  • 特に肝機能悪化の問題について

Search this article

Abstract

Effects and side effects of oral antitumor agents were investigated in 86 patients with hepatocelular carcinoma treated by transcatheter arterial embolization (TAE). Almost all cases were associated with liver cirrhosis. Patients were classified into three groups as follows: 27 with tegafur 600mg/day administration after TAE (group A), 25 with UFT (compound of tegafur 400mg/day and uracil) administration after TAE (group B), and 34 without any anticancer drug after TAE (group C).<br>Tumor necrosis rates at the time of 3 months and 6 months after TAE were better in groups A and B than that in group C. One-year survival rates after TAE were slightly better in groups A and B, but no significant difference was shown among 3 groups when statistical correction was made by stratification of tumor staging.<br>Appearance rates of ascites and/or encephalopathy within 6 months were significantly higher in groups A and B than in group C (33.3%, 30.4%, 5.9%, respectively, p<0.05). Various liver function tests were more aggravated in group A and B in the clinical course. Long term use of anticancer drugs may worsen liver reserves, and they should be cautiously administered for hepatocellular carcinoma associated with liver cirrhosis.

Journal

Citations (1)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top